Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intensity Therapeutics Inc (INTS)

Intensity Therapeutics Inc (INTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,089
  • Shares Outstanding, K 60,065
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,270 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 3.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.20
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings $-0.06 on 11/06/25
  • Next Earnings Date 03/12/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +77.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3510 +19.00%
on 12/02/25
0.6000 -30.38%
on 12/12/25
-0.0097 (-2.27%)
since 11/19/25
3-Month
0.2222 +87.98%
on 09/25/25
1.7400 -75.99%
on 10/30/25
+0.1693 (+68.16%)
since 09/19/25
52-Week
0.1853 +125.42%
on 08/01/25
3.1663 -86.81%
on 01/16/25
-1.5823 (-79.11%)
since 12/19/24

Most Recent Stories

More News
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn. , Dec. 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

SHELTON, Conn. , Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn. , Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SHELTON, Conn. , Nov. 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

SHELTON, Conn. , Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety

INTS : 0.4104 (-1.75%)
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Major biotechnology companies are presenting multi-cancer detection data and breakthrough clinical results...

INTS : 0.4104 (-1.75%)
GRAL : 91.09 (+3.14%)
GTBP : 0.7569 (+3.02%)
PFE : 25.19 (+0.60%)
CCCC : 2.03 (+1.00%)
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

SHELTON, Conn. , Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

SHELTON, Conn. , Sept. 2, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery...

INTS : 0.4104 (-1.75%)
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

SHELTON, Conn. , Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery...

INTS : 0.4104 (-1.75%)

Business Summary

Intensity Therapeutics Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx(SM) technology platform to create new, proprietary drug formulations, following direct injection, rapidly disperse throughout a tumor...

See More

Key Turning Points

3rd Resistance Point 0.4668
2nd Resistance Point 0.4499
1st Resistance Point 0.4338
Last Price 0.4104
1st Support Level 0.4008
2nd Support Level 0.3839
3rd Support Level 0.3678

See More

52-Week High 3.1663
Fibonacci 61.8% 2.0276
Fibonacci 50% 1.6758
Fibonacci 38.2% 1.3240
Last Price 0.4104
52-Week Low 0.1853

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar